Business
Incyte completes USD 2b Vega acquisition for VWD antibody
Incyte (Nasdaq: INCY) has completed its acquisition of Vega Therapeutics, Inc., a wholly owned subsidiary of San Francisco-based Star Therapeutics LLC,...
Otsuka's Astex strikes USD 515m breast cancer deal with Genentech on FBDD platform
Genentech has entered an exclusive worldwide research collaboration and license agreement with UK-based Astex Pharmaceuticals, paying USD 25 million upfront...
Scribe Therapeutics files for Nasdaq IPO with clinical-stage cardiovascular CRISPR pipeline
Scribe Therapeutics Inc. (Nasdaq: SCTX), a clinical-stage gene editing company co-founded by Nobel Laureate Dr. Jennifer Doudna and backed by more than USD...
Novartis acquires Myricx Bio's NMTi platform to reshape ADC resistance and tolerability
Novartis has agreed to acquire UK-based Myricx Bio for up to USD 1.5 billion, adding a preclinical N-myristoyltransferase inhibitor (NMTi) payload platform...
AstraZeneca expands CSPC partnership with up to USD 1.77b kidney siRNA deal
AstraZeneca has struck its third deal with CSPC Pharmaceutical Group Limited (HKEX: 1093) in under two years, agreeing to a collaboration, option and...
United Therapeutics bets USD 300m on iPSC thymic cell therapies with Thymmune acquisition
United Therapeutics Corporation (Nasdaq: UTHR) has acquired Thymmune Therapeutics, Inc., a privately held, preclinical-stage biotechnology company...
Elicio raises USD 15m to launch Phase I study of KRAS-targeted immunotherapy in pancreatic cancer
Boston-based Elicio Therapeutics, Inc. (Nasdaq: ELTX) announced a USD 15 million registered direct offering on July 2, 2026, with proceeds directed...
Celea raises USD 180m to launch first head-to-head superiority trial in IPF
Boston-based Celea Therapeutics announced the completion of a USD 180 million private placement to fund initiation of a pivotal Phase III trial in...
BridgeBio secures USD 1b to scale Attruby launch and fund three incoming programs
Palo Alto-based BridgeBio Pharma, Inc. (Nasdaq: BBIO) announced a USD 1 billion private placement of Series A Cumulative Convertible Participating Preferred...
AlzeCure licenses first-in-class Alzheimer's drug to QuantumCell for USD 2.2b
Sweden-based AlzeCure Pharma AB (STO: ALZCUR) has out-licensed global rights to its NeuroRestore platform and lead ACD856 drug candidate to Denmark-based...
European Investment Bank backs Orano's lead-212 isotope supply chain with EUR 125m facility loan
France's Orano secures EIB development loan to fund lead-212 cancer therapy infrastructure, with the EU's backing reflecting both the clinical and...
Neurogene raises USD 125m to accelerate Rett syndrome gene therapy toward approval
New York-based Neurogene Inc. (Nasdaq: NGNE) announced the pricing of a USD 125 million public offering of common stock and pre-funded warrants on July 1,...
Alvotech secures USD 75m term loan to fund FDA resubmissions and global launches
Iceland-based Alvotech (Nasdaq: ALVO) announced a USD 75 million term loan facility on July 1, 2026, adding non-dilutive debt capital to fund R&D pipeline...
Lonza reshapes CDMO model with proprietary CNS delivery platform acquisition from Nona
Lonza has struck a deal to acquire IP rights to Nona Biosciences' single-domain antibody BBB-crossing technology, marking an unusual move by the Swiss CDMO...
Abbisko to pair oral PD-L1 inhibitor with AstraZeneca's Tagrisso in combination trial for NSCLC
Shanghai-based Abbisko Therapeutics (HKEX: 02256.HK) has entered a clinical collaboration with AstraZeneca (NYSE: AZN) to evaluate lumipodlin (ABSK043), a...
The AllSci Brief
Systematic R&D and deal news. Daily.